Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two years.

Pick the best stocks and maximize your portfolio: Sami Corwin has given his Buy rating due to a combination of factors surrounding uniQure’s progress with its AMT-130 gene therapy for Huntington ...

This regulatory clarity enhances confidence in uniQure’s ability to prioritize and advance their lead gene therapy while managing other developmental programs. Additionally, the recent positive ...

Shares of uniQure surged on Dec. 10 after the company gave investors great news regarding AMT-130, an experimental gene therapy it's developing to treat Huntington's disease.

Shares of uniQure have more than doubled in December. The company is developing a gene therapy to treat Huntington's disease called AMT-130. UniQure recently said the Food and Drug Administration ...

LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical ...

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the ...

On Thursday, Mizuho (NYSE:MFG) Securities updated its perspective on uniQure BV (NASDAQ:QURE), a biotechnology company specializing in gene therapy. The firm increased its price target for uniQure ...

uniQure’s share price has more than doubled following positive interim data from two Phase I/II studies investigating its gene therapy for Huntington’s disease. In patients in the high-dose ...

The gene therapy leader, uniQure, has confirmed its alignment with the FDA on pivotal aspects of AMT-130's Accelerated Approval pathway. The FDA's Center for Biologics Evaluation and Research ...